- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00999050
Laparoscopic Gastric Bypass for Type 2 Diabetes Mellitus With Body Mass Index (BMI) < 35
Laparoscopic Gastric Bypass for Type 2 Diabetes Mellitus: a Pilot Prospective Study in Overweight and Mildly Obese Subjects
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The primary endpoint will be the reduction of HbA1c and secondary endpoints will be multiple associated parameters as listed below. A group of 50 subjects with medically documented T2DM and BMI of 26-35 will undergo standard laparoscopic RYGB. Prior to surgery, the subjects will undergo the standard pre-operative work up required for conventional bariatric surgery. This includes full history and physical exam, medical/cardiac clearances as needed, nutrition consultation and a gastrointestinal consultation for upper endoscopy. After thorough explanation an approved informed consent will be signed. Baseline parameters, as listed below, will be measured for each subject to identify possible complications of diabetes prior to the surgical intervention..
After surgery perioperative complications will be monitored and required modifications of diabetes management advised. Followed up measurements at 1, 3, 6, 12, and 24 months is consistent with standard clinical practice guidelines. Data analysis will be ongoing to observe the effects of the surgical intervention on glucose homeostasis.
- Baseline parameters
- History and Physical Exam
- Weight/BMI/ body composition with the Tanita 310.
- Waist Circumference
- Blood Pressure
- CBC
- HbA1c
- Fasting glucose
- Vitamin B6, B12, Folate,and Iron status
- Lipid Profile -total cholesterol, HDL, LDL, triglyceride
- Fasting Insulin and C-peptide
- Stimulated C-peptide
- EKG
- Retinal exam
- Urinalysis (assess for proteinuria and microalbuminuria)
- Comprehensive foot exam
- Medications and dosage
- Quality of Life Score (SF-36)
- Carotid ultrasound (intima-media thickness)
Follow-up:
4 Weeks:
- Physical Examination, wound check, Body weight, BMI,
- Glucose Diary (pre and postprandial glucose levels as required)
- Insulin and C-peptide
- Lipid profile
Medication use
3 Months, 6 months,
Same as above plus:
- HbA1c
- Vitamin levels and iron status
- Retinal exam
- Annually the baseline measurements will be repeated
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Maureen Morrison, MSN-ACNP, DNPc
- Phone Number: 212-746-5925
- Email: msm7003@med.cornell.edu
Study Contact Backup
- Name: Tina Chuck, MPH
- Phone Number: 212-746-5725
- Email: tic2005@med.cornell.edu
Study Locations
-
-
New York
-
New York, New York, United States, 10065
- Recruiting
- Weill Cornell Medical College New York Prysbyterian Hosptial
-
Contact:
- Francisco Rubino, MD
- Phone Number: 212-746-5925
- Email: frr2007@med.cornell.edu
-
Contact:
- Gladys W Strain, PhD
- Phone Number: 212-746-5661
- Email: gls2010@med.cornell.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Adult males and females who meet the following inclusion criteria will be offered the opportunity to participate in the study:
Diagnosis of type 2 Diabetes Mellitus (T2DM) confirmed by the following criteria:
- normal or high C-peptide level (> 0.9 ng/ml) to exclude type 1 Diabetes Mellitus
- positive glucagon test to confirm T2DM
- fasting plasma glucose of 126 mg/dl or more on at least two occasions
- Body mass index (BMI) 26 kg/m2 or greater, and less than 35 kg/m2
- History of T2DM for not longer than 8 years, as long-standing disease beyond 8 years correlates with failure to achieve diabetes resolution after gastric bypass
- No contraindication for surgery or general anesthesia as determined by a multidisciplinary bariatric surgery team (surgeon, anesthesiologist, internist, dietitian, psychologist)
- Between 18 and 65 year of age
- Able to provide informed consent
- If a female with reproductive potential, she has to agree to use a reliable method of birth control for at least one year from the date of surgery
Exclusion Criteria
Subjects who meet any of the following exclusion criteria will not be eligible to participate in the study:
- Enrollment in another clinical study, which involves an investigational drug
- Diagnosis of type 1 Diabetes Mellitus or other genetic forms of Diabetes Mellitus
- Significant renal failure of chronic liver disease (except NAFLD)
- Major psychological disorders
- Pregnancy - all female subjects will have serum beta-hCG prior to operation, and must use birth control of their choice to avoid pregnancy during the first year after surgery
- Previous gastric or esophageal surgery
- Immunosuppressive drugs including corticosteroids
- Coagulopathy defined as an INR > 1.5 or platelet count < 50,000/µl
- Anemia defined as a Hb <10.0 g/dl
- Inflammatory bowel diseases or other medical condition that would serve as a contraindication to gastric bypass (eg. celiac sprue, pancreatic insufficiency)
- A severe concurrent illness that is likely to limit life or require extensive systemic treatment (e.g. cancer)
A pre-existing major complication of diabetes:
- unstable, proliferative retinopathy
- severe autonomic cardiac neuropathy or intestinal neuropathy
- Myocardial infarction within the previous year, current unstable angina, or poorly-controlled congestive heart failure (Stage III)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: diabetic pts <35BMI
All patients will be in a single arm receiving bypass surgery to assist with diabetes management
|
The operation is performed under general anesthesia.
It is done laparoscopically, meaning that several small openings are made in the abdomen for insertion of long, thin surgical instruments, one with an attached camera.
The operation is video monitored.
The top of the stomach is divided across, leaving a small pouch for food.
The rest of the stomach remains but can receive no food.
The gut is divided just past the stomach, and it is attached to the small stomach pouch so that food can get back into the bowel.
A second connection is made so that the bile and digestive juices pass into the bowel with the food.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Hemoglobin A1C changes
Time Frame: Post gastric bypass operation
|
Post gastric bypass operation
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
improvement in glycemic control
Time Frame: 1 to two years
|
1 to two years
|
Collaborators and Investigators
Publications and helpful links
General Publications
- Cohen R, Pinheiro JS, Correa JL, Schiavon CA. Laparoscopic Roux-en-Y gastric bypass for BMI < 35 kg/m(2): a tailored approach. Surg Obes Relat Dis. 2006; 2(3):401-4. Cohen RV, Schiavon CA, Pinheiro JS, Correa JL, Rubino F. Duodenal-jejunal bypass for the treatment of type 2 diabetes in patients with body mass index of 22-34 kg/m2: a report of 2 cases. Surg Obes Relat Dis. 2007; 3(2): 195-7. Lee WJ, Wang W, Lee YC, Huang MT, Ser KH, Chen JC. Effect of laparoscopic mini-gastric bypass for type 2 diabetes mellitus: comparison of BMI>35 and <35 kg/m2. J Gastrointest Surg. 2008; 12(5): 945-52. Scopinaro N, Papadia F, Marinari G, Camerini G, Adami G. Long-term control of type 2 diabetes mellitus and the other major components of the metabolic syndrome after biliopancreatic diversion in patients with BMI < 35 kg/m2. Obes Surg. 2007; 17(2): 185-92. Chiellini C, Rubino F, Castagneto M, Nanni G, Mingrone G. The effect of bilio-pancreatic diversion on type 2 diabetes in patients with BMI <35 kg/m2. Diabetologia. 2009; 52(6): 1027-30.
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 0906010450
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Type 2
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
AstraZenecaRecruiting
-
Daewoong Pharmaceutical Co. LTD.Not yet recruitingT2DM (Type 2 Diabetes Mellitus)
-
Zhongda HospitalRecruitingType 2 Diabetes Mellitus (T2DM)China
-
Newsoara Biopharma Co., Ltd.RecruitingT2DM (Type 2 Diabetes Mellitus)China
-
Shanghai Golden Leaf MedTec Co. LtdActive, not recruitingType 2 Diabetes Mellitus (T2DM)China
Clinical Trials on Gastric bypass for diabetic patients <35 BMI
-
Cairo UniversityUnknown
-
University of AarhusCompletedComplications After Bariatric SurgeryDenmark
-
Vanderbilt UniversityCompletedType 2 Diabetes Mellitus | Obese PatientsUnited States
-
University Medical Center, KazakhstanWithdrawn
-
Paulo Reis Esselin de MeloHospital Estadual Geral de Goiânia Dr. Alberto RassiUnknown
-
Tata Memorial HospitalUnknown
-
University Hospital, BordeauxRecruitingDiabetes Mellitus, Type 2France
-
Hospital Alemão Oswaldo CruzJohnson & Johnson Pharmaceutical Research & Development, L.L.C.CompletedComplications of Diabetes MellitusBrazil
-
Sanidad de Castilla y LeónCompletedImprovement of Diabetic Foot Care in Salamanca Through the Implementation of Standardized Protocols.Diabetes | Diabetic Foot | Primary Health CareSpain
-
Hangzhou Tangji Medical Technology Co., Ltd.Not yet recruitingNonalcoholic Fatty Liver Disease